QIAGEN NV has announced a new partnership with ID Solutions, a French company specializing in digital PCR assays and molecular testing solutions for oncology. This collaboration aims to enhance QIAGEN's leadership in oncology-focused digital PCR assays by expanding the availability of these assays for non-clinical oncology research. The partnership will leverage QIAGEN's global reach and automation expertise alongside ID Solutions' assay development and manufacturing capabilities. Under the agreement, ID Solutions will produce dPCR assays for use on QIAGEN's QIAcuity platforms, optimized to detect multiple mutations in various DNA samples. Initially launching in Europe, this partnership is set to broaden QIAGEN's portfolio and support the adoption of the QIAcuity dPCR platform in cancer research.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.